SYS-CON MEDIA Authors: Pat Romanski, Doug Masi, Mat Mathews, PR.com Newswire, David Smith

News Feed Item

Trimel Announces Appointment of Tom Rossi to Its Board of Directors

TORONTO, ONTARIO -- (Marketwired) -- 01/16/14 -- Trimel Pharmaceuticals Corporation (TSX:TRL) today announced the appointment of Mr. Tom Rossi, the company's President and Chief Executive Officer, to its Board of Directors, effective January 21, 2014.

Mr. Rossi joined Trimel in August, 2011, and was appointed President and Chief Executive Officer in January, 2013. He has over 25 years experience in the pharmaceutical industry in Canada and abroad. He previously worked for Johnson & Johnson, Boehringer Mannheim, Merck & Co. and Novartis. As Chief Executive Officer of Novartis Pharmaceuticals Canada Inc., Mr. Rossi led Canada's fourth largest pharmaceutical company with annual sales in excess of $800 million and over 700 employees while delivering significant levels of profitability to the corporation. Mr. Rossi is a native of Montreal where he graduated from McGill University, majoring in Microbiology and Immunology, and holds an MBA from Concordia University.

Mr. Ian Ihnatowycz, Chair of the Board of Directors of Trimel stated, "The Board joins me in welcoming Tom as a Director. His corporate knowledge, experience, and leadership have been important in his continuing role as CEO, and will be vital as Trimel embarks on a new phase of growth and development."

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT(TM), a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.